Comparative Pharmacology
Head-to-head clinical analysis: HYDRALAZINE HYDROCHLORIDE W HYDROCHLOROTHIAZIDE 25 25 versus HYDRODIURIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDRALAZINE HYDROCHLORIDE W HYDROCHLOROTHIAZIDE 25 25 versus HYDRODIURIL.
HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 25/25 vs HYDRODIURIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydralazine is a direct-acting arteriolar vasodilator that reduces peripheral resistance through relaxation of vascular smooth muscle, likely via nitric oxide-mediated increases in cGMP. Hydrochlorothiazide is a thiazide diuretic that inhibits the Na+/Cl- cotransporter in the distal convoluted tubule, reducing sodium and water reabsorption and decreasing plasma volume.
Inhibits sodium-chloride symporter in the distal convoluted tubule of the kidney, increasing excretion of sodium and water, reducing plasma volume and cardiac output.
One tablet orally twice daily, titrated based on blood pressure response; maximum dose: one tablet four times daily.
25-100 mg orally once daily. For hypertension: 12.5-25 mg once daily.
None Documented
None Documented
Hydralazine: 2-8 hours (terminal half-life; prolonged in renal impairment; acetylator phenotype affects clearance); Hydrochlorothiazide: 6-15 hours (terminal half-life; increased in renal impairment).
Terminal elimination half-life is approximately 5.6–14.8 hours (mean ~10 hours); clinically, duration of diuresis correlates with half-life, allowing once or twice daily dosing.
Hydralazine: 80% renal (as metabolites, 5-10% unchanged); Hydrochlorothiazide: 95% renal (as unchanged drug).
Renal: approximately 95% eliminated unchanged in urine via glomerular filtration and tubular secretion; biliary/fecal: <5%.
Category A/B
Category C
Thiazide Diuretic
Thiazide Diuretic